Summary: ProSomnus Inc, specializing in oral appliance remedy for obstructive slumber apnea, claimed a 43% enhance in 2023 income to $27.7 million, marking its eighth consecutive quarter of history earnings. Development was attributed to the adoption of its EVO item, elevated … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]